BMYBristol-Myers Squibb Co.
BMY
Bristol-Myers Squibb Co.20,696
Mkt Cap
$119.22BVolume
7.91M52W High
$62.8952W Low
$42.52PE Ratio
16.93BMY Fundamentals
Price
$58.54Prev Close
$59.43Open
$59.6150D MA
$58.75Beta
0.32Avg. Volume
13.86MEPS (Annual)
$3.46P/B
6.45Rev/Employee
$1.48M$146,482.66
Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Bristol Myers Squibb (NYSE: BMY) today announced positive data from the Phase 3 SCOUT-HCM trial of Camzyos (mavacamten), the first study of a cardiac myosin inhibitor (CMI) in adolescents (ages 12...
Business Wire·5h ago
Wedge Capital Management L L P NC Decreases Stake in Bristol Myers Squibb Company $BMY
Wedge Capital Management L L P NC cut its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 3.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 563,410 shares of the biopharmaceutical co...
MarketBeat·1d ago
Nepsis Inc. Acquires 90,852 Shares of Bristol Myers Squibb Company $BMY
Nepsis Inc. raised its holdings in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 49.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The...
MarketBeat·1d ago
Pallas Capital Advisors LLC Buys 63,750 Shares of Bristol Myers Squibb Company $BMY
Pallas Capital Advisors LLC increased its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 196.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 96,157 shares of the biopharmaceutical company's stock after purchasing an additiona...
MarketBeat·1d ago
Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy (xanomeline and trospium chloride)
Bristol Myers Squibb (NYSE: BMY) today announced data from a Phase 4 clinical trial evaluating the symptom stability, safety and tolerability of Cobenfy (xanomeline and trospium chloride) when...
Business Wire·1d ago
Can MRK's Ongoing M&A Push Aid Long-Term Growth Ahead of Keytruda LOE?
Merck's recent M&A spree, including its $6.7B Terns deal, aims to diversify its pipeline and revenue base as Keytruda nears its 2028 exclusivity loss.
Zacks·2d ago
Can Gilead's Recent Acquisitions Strengthen Its Long-Term Growth Outlook?
Gilead doubles down on acquisitions, adding immunology and CAR-T assets to diversify beyond HIV and strengthen its oncology pipeline.
Zacks·2d ago
Norden Group LLC Acquires 157,604 Shares of Bristol Myers Squibb Company $BMY
Norden Group LLC raised its holdings in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 816.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 176,915 shares of the biopharmaceutical company's stock after buying a...
MarketBeat·2d ago
Fort Washington Investment Advisors Inc. OH Increases Stock Holdings in Bristol Myers Squibb Company $BMY
Fort Washington Investment Advisors Inc. OH raised its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 1.5% in the fourth quarter, according to the company in its most...
MarketBeat·2d ago
FY2026 Earnings Forecast for BMY Issued By Erste Group Bank
Bristol Myers Squibb Company (NYSE:BMY - Free Report) - Investment analysts at Erste Group Bank lifted their FY2026 earnings estimates for shares of Bristol Myers Squibb in a research note issued on Tuesday, March 24th. Erste Group Bank analyst H. Engel now forecasts that the biopharmaceutical compa...
MarketBeat·3d ago
<
1
2
...
>